Eczema Drug Dupilumab Shows Promise Against Stubborn IgG4-Related Disease

A drug already famous for calming the inflamed skin of eczema patients may have a second act, and it could be a dramatic one. In a new report published in Archives of Dermatological Research, a team of dermatologists at The Ohio State University describes two patients with stubborn, treatment-resistant IgG4-related disease whose symptoms improved after treatment with dupilumab, a monoclonal antibody that blocks the signaling pathways of two immune messenger molecules, interleukin-4 and interleukin-13. Combined with a systematic review of thirteen previously reported cases, the findings offer the most encouraging preliminary evidence yet that this biologic therapy could help patients with a rare and poorly understood fibroinflammatory disorder that has few good treatment options.

IgG4-related disease is an enigmatic condition in which immune cells called IgG4-positive plasma cells infiltrate tissues throughout the body, triggering chronic inflammation and, ultimately, the formation of dense fibrous scar tissue. This multiorgan fibrosis can strike nearly any part of the anatomy: the salivary and lacrimal glands, the pancreas, the kidneys, the lungs, the thyroid, and, in a substantial minority of patients, the skin. Diagnosis is notoriously tricky, resting on a combination of clinical examination, elevated serum IgG4 concentrations, and characteristic histopathological findings on biopsy. The 2019 classification criteria developed by the American College of Rheumatology and the European League Against Rheumatism have helped standardize diagnosis, but the underlying biology of the disease remains incompletely characterized, leaving clinicians without a targeted therapy designed specifically for it.

That gap in understanding is precisely where dupilumab enters the picture. Although the complete pathophysiology of IgG4-related disease has not been fully mapped, researchers have identified two molecular culprits that make it an attractive target. Interleukin-4 is the cytokine that drives immunoglobulin class switching, coaxing B cells into producing the IgG4 antibodies that give the disease its name. Interleukin-13, its close molecular relative, is a well-established mediator of fibrosis, the scarring process that can permanently damage organs in advanced disease. Dupilumab works by binding the interleukin-4 receptor alpha subunit, a shared signaling gateway that both interleukin-4 and interleukin-13 require to transmit their instructions into cells. Blocking that gateway simultaneously silences two processes central to the disease: the production of IgG4 antibodies and the fibrotic remodeling of tissue.

The drug is no stranger to dermatology clinics. Approved for moderate-to-severe atopic dermatitis, dupilumab has demonstrated favorable safety and sustained efficacy in open-label studies extending up to three years, and it has since been deployed against a growing list of inflammatory skin and airway conditions. Its mechanism, however, makes it uniquely suited to IgG4-related disease in theory, because no other approved therapy hits both the class-switching and fibrotic arms of the pathology at once. Traditional immunosuppressants blunt the immune system broadly, while rituximab, the most effective agent currently available, depletes B cells entirely and carries its own risks and limitations.

The Ohio State team, led by Diana Hallak and colleagues in the Department of Dermatology, presents two cases that illustrate both the promise and the complexity of this approach. The first patient, a 54-year-old woman with a history of Hashimoto’s thyroiditis, presented with a generalized, intensely itchy papular rash. Biopsy findings and elevated serum IgG4 levels confirmed a diagnosis of IgG4-related disease. She initially failed treatment with mycophenolate mofetil, an immunosuppressant commonly used as a steroid-sparing agent. When dupilumab was started, her rash improved substantially, a striking response for a patient whose disease had resisted conventional therapy. Yet her course was not straightforward: she later experienced recurrent flares despite continuing the drug, requiring further adjustments to her medication regimen.

The second patient tells a more uniformly triumphant story. A 42-year-old woman had IgG4-related disease affecting both her lacrimal glands, the structures that produce tears, and her skin. After multiple treatment failures, she began dupilumab and achieved sustained control of her disease. For a condition that can progressively destroy glandular tissue and disfigure the periorbital region, durable remission on a well-tolerated biologic represents a meaningful clinical win. The contrast between the two patients, one with lasting benefit and one with breakthrough flares, underscores an important caveat: dupilumab may not produce uniform or permanent responses, and some patients may need combination or sequential strategies.

To place these two cases in context, the authors conducted a systematic review of the published literature, identifying thirteen additional cases of IgG4-related disease treated with dupilumab. The pattern across those reports is striking. In all but one of the published case reports, dupilumab consistently improved clinical symptoms and reduced serum IgG4 levels, the laboratory marker most closely watched by clinicians managing the disease. Reported successes span a wide range of manifestations, including dacryoadenitis and sialoadenitis, steroid-dependent disease complicated by asthma, aspirin-exacerbated respiratory disease overlapping with IgG4-related disease, and the adult-onset asthma and periocular xanthogranuloma syndrome that overlaps with IgG4-related pathology. In at least one reported case, dupilumab monotherapy was sufficient to induce remission of IgG4-related dacryoadenitis and sialoadenitis, suggesting the drug may work even without additional immunosuppression in some patients.

The immunological rationale behind these observations runs deeper than the two cytokines alone. Studies of patients with IgG4-related disease have revealed a characteristic skewing of the T cell compartment toward type 2 helper responses, with expansions of circulating follicular helper 2 T cells, a specialized subset that supports B cell antibody production. The numbers of these cells correlate with serum IgG4 levels, interleukin-4 concentrations, and plasmablast counts, the short-lived antibody-secreting cells that many researchers consider a more dynamic biomarker of disease activity than serum IgG4 itself. In other words, the type 2 immune axis that dupilumab shuts down is not a peripheral player in IgG4-related disease; it appears to be the engine driving the entire process. Blocking the interleukin-4 receptor is therefore a mechanistically precise intervention, not a blunt instrument.

Still, the evidence base remains thin, and the authors are careful about what their findings can and cannot support. Every data point in the review comes from individual case reports and small case series, study designs that are vulnerable to publication bias, since dramatic successes are far more likely to be written up than failures. There have been no randomized controlled trials of dupilumab in IgG4-related disease, no standardized dosing regimens, and no long-term safety data specific to this population. The first patient’s breakthrough flares are a reminder that initial response does not guarantee durable remission. The existing comparator, rituximab, has been evaluated in systematic reviews and meta-analyses showing efficacy both as induction and maintenance therapy, so any future role for dupilumab will need to be defined relative to that benchmark, whether as an alternative for patients who fail or cannot tolerate rituximab, or as part of a steroid-sparing strategy.

What the new report does provide is a clear signal worth testing. Fifteen patients across the literature and the new cases, most of them with disease that had defeated multiple prior therapies, overwhelmingly improved on dupilumab, with reductions in both symptoms and serum IgG4. The authors conclude that dupilumab appears efficacious in recalcitrant IgG4-related disease and emphasize that these encouraging preliminary findings underscore the need for formal clinical trials to optimize dosing regimens and evaluate long-term efficacy and safety. For patients with a disease that can silently scar organs and for whom options have long been limited to broad immunosuppression, the prospect of a targeted, well-tolerated therapy that attacks both the antibody production and the fibrosis at the heart of the condition is a reason for genuine optimism. The next step, a properly controlled trial, will determine whether dupilumab’s second act becomes standard of care.

Subject of Research: Dupilumab therapy for treatment-resistant IgG4-related disease

Article Title: Dupilumab therapy for recalcitrant IgG4-related disease: case series and literature review

Article References: Hallak, D., Quadri, I., Awethe, Z., Kirven, R. M., Pettit, C., & Kaffenberger, J. (2026). Dupilumab therapy for recalcitrant IgG4-related disease: case series and literature review. Archives of Dermatological Research, 318(1), Article 425. https://doi.org/10.1007/s00403-026-04941-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04941-9

Keywords: IgG4-related disease, dupilumab, interleukin-4, interleukin-13, biologics, immunotherapy, fibroinflammatory disease, plasma cells, rituximab, case series, dermatology, autoimmune disease